Viking Therapeutics Shares Decline Following Mixed Clinical Trial Results

Viking Therapeutics finds itself navigating significant market headwinds in the wake of recent clinical data presentations. The company’s stock experienced a substantial decline, falling more than 20 percent during the previous month and now trading well below key moving averages. This downward pressure stems from growing investor apprehension regarding the tolerability profile of Viking’s oral weight-loss drug candidate, VK2735, which has overshadowed its demonstrated efficacy.

The biopharmaceutical company remained in the investor spotlight following its participation in the Morgan Stanley Global Healthcare Conference on September 8. However, the event failed to generate positive momentum. Instead, market participants have intensified their focus on concerns about the development trajectory of VK2735 within the highly competitive obesity treatment landscape.

While the Phase 2 study... Read more...